The clinical development history of gantenerumab, a subcutaneous anti-Aβ monoclonal antibody for early Alzheimer’s disease: Building on lessons from the past and paving a path for the future

The clinical development of gantenerumab, has been informed by two decades of sustained scientific investigation in Alzheimer’s disease. In light of the resutls of the two Phasae III pivotal studies, GRADUATE I & II reading out in Q4 2022, this session will provide an overview of key insights informing decision on the gantenerumab progrmame and the wider field, as treatment strategies moves towards even earlier interventions in prevention, and as efforts intensify to advance inclusive research and prioritize disease management flexibility for people with Alzheimer’s and their care partners.